Genfit, Ipsen: Positive Results from Phase III biliary cholangitis trial

 

• Trial met primary endpoint with a statistically significant higher percentage of patients achieving a clinically meaningful cholestasis response compared to placebo

• Elafibranor was well tolerated with a safety profile consistent with previous studies

• Results position elafibranor as a potentially important new treatment option, where there is still high unmet need

• Ipsen intends to submit regulatory applications for elafibranor following discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)

• GENFIT conference call (English and French) on June 30 at 8am ET / 1pm GMT / 2pm CET

GENFIT will host a conference call on June 30, 2023 at 8:00am ET / 1:00pm GMT / 2:00pm CET in English and in French

Both the English and French conference calls will be accessible on the investor page of our website, under the events section at https://ir.genfit.com/ or by calling 888-394-8218 (toll-free U.S. and Canada), 0800 279 0425 (toll-free UK) or 0805 101 219 (France) five minutes prior to the start time (confirmation code: 6752821). A replay will be available shortly after the call.

https://finance.yahoo.com/news/ipsen-genfit-announce-positive-results-050000395.html